UROGEN PHARMA LTD (URGN) Stock Income Statement
NASDAQ:URGN - Nasdaq - IL0011407140 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 90.40M | 82.71M | 64.36M | 48.04M | 11.80M | |||
| Cost Of Goods | 8.88M | 9.36M | 7.65M | 5.16M | 1.01M | |||
| Gross Profit | 81.52M | 73.35M | 56.70M | 42.89M | 10.79M | |||
| Operating Expenses | 178.30M | 138.89M | 135.75M | 135.17M | 137.53M | |||
| Research and Development | 57.15M | 45.61M | 52.91M | 47.64M | 47.31M | |||
| Selling, General, and Administrative Expenses | 121.15M | 93.27M | 82.84M | 87.54M | 90.22M | |||
| Operating Income | -96.78M | -65.54M | -79.04M | -92.29M | -126.74M | |||
| Interest Income/Expense | -3.62M | -12.07M | -7.50M | 370.00K | 1.99M | |||
| Other Income/Expense | -23.64M | -20.71M | -21.49M | -17.44M | -360.00K | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -124.04M | -98.32M | -108.03M | -109.37M | -125.11M | |||
| Income Tax | 2.83M | 3.92M | 1.76M | 1.45M | 3.37M | |||
| Net Income | -126.87M | -102.24M | -109.78M | -110.82M | -128.48M | |||
| EBITDA | -96.45M | -64.73M | -78.12M | -91.46M | -126.32M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.96 | -3.55 | -4.81 | -4.96 | -5.90 | |||
| Non GAAP EPS | -3.23 | -3.73 | -4.78 | -4.96 | -5.92 | |||
| Statistics | ||||||||
| Gross Profit Margin | 90.18% | 88.68% | 88.10% | 89.28% | 91.44% | |||
| Profit Margin | -140.35% | -123.61% | -170.57% | -230.68% | -1088.81% | |||
| Operating Profit Margin | -107.06% | -79.23% | -122.81% | -192.11% | -1074.07% | |||
All data in USD